Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Multiple Myeloma Physicians

Articles with lock require a subscription to GLG News | Request a free trial
August 15, 2008
BiovaxID: Does It Work?
Analysis of: Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial | biz.yahoo.com
Author: Donald Tsai, Assistant Professor of Medicine, University of Pennsylvania Cancer Center
1) BiovaxID shows a 100% improvement in DFS at 3 years (p=0.24) 2) BiovaxID shows an improvement in median overall DFS with a significant P value (p=0.047) 2) This is the first lymphoma vaccine with a suggestion of activity. 3) BiovaxID shows evidence of activity despite the failure of 2 other...
Donald FlemingAugust 14, 2008
UK the model for US healthcare?
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
In this election year some have encouraged adoption of socialized medical services UK healthcare is an example of what some in this country have said we need to model our future healthcare system The recent use of biologics such as the TKIs have resulted in options for...
August 13, 2008
Hepcidine quantification is a valuable tool for iron balance analysis
Analysis of: UCLA And Biotech Company Develop First Blood Test To Measure Key Hormone That Regulates Iron | www.medicalnewstoday.com
Author: GLG Expert Contributor
Hepcidine is a key regulator of iron balence. Despite the availability of some iron makers (ferritin, sideremia and transferrin), hepcidine dosage can aid in the interpretation of complex clinical cases. However, its use could be limited to very particular clinical cases.
August 13, 2008
"Health-care costs are expected to rise more than 10% ".... and we can continue this for how long??
Analysis of: Insurers Expect Health-Care Costs To Rise More Than 10% Next Year | online.wsj.com
Author: GLG Expert Contributor
10% increase in medical spending when the overall cost of living is 1/2 of medical costs and we are happy??
August 11, 2008
Fair or Unfair Decision: the cost of the drugs for kidney cancer is more than the economy can bear.
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: GLG Expert Contributor
Pfizer’s Sutent, Wyeth’s Torisel, Bayer’s Nexavar and Avastin, sold by Roche and Genentech have been deemed too expensive to be paid for by UK agencies
August 7, 2008
Salmonella; Cancer cells?? Let's not get carried away
Analysis of: Salmonella Is Tested To Fight Cancer Cells | online.wsj.com
Author: GLG Expert Contributor
Salmonella targeting cancer cells? In humans???
August 6, 2008
Boy will this p.... off Urologists as well as AARP!
Analysis of: Panel Urges End to Prostate Screening at Age 75 | www.nytimes.com
Author: GLG Expert Contributor
Since treatment may be worse than the disease it is being recommended that routine prostate cancer screening be stopped after the age of 75.
July 31, 2008
Amgen and J & J: Not hurt as much as we had predicted.
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: GLG Expert Contributor
Amgens Aranesp sales fell 26% and J & J's Procrit sales fell 23%."Yaron Werber, a biotechnology analyst at Citi Investment Research, estimated that the new label could reduce the use of Aranesp for cancer patients in this country — the drug is also used by people with kidney disease — by an additional...
July 31, 2008
Lung Cancer Screening: Here we go again.
Analysis of: Corrections Weaken Cancer Study | online.wsj.com
Author: GLG Expert Contributor
Lung cancer screening does not appear to prevent death at least in this study.
July 30, 2008
Avastin may not get approval of "cost-conscious" EMEA
Analysis of: Roche Files Avastin for Wider Label in EU | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Avastin ( Roche/Genentech) extended time to progression when combined with Docotaxel ( Sanofi-Aventis) in patients with metastatic breast cancer as compared to Docotaxel alone, but did not prolong survival. Unlike approval by the FDA,the EMEA is more cost conscious and may be reluctant to...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next31 to 40 of 854

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-10-11T13:45:17.197